Browse

The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.

A group of coming decisions could provide important insights into how flexible the agency is willing to be under new leadership.

According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.